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Abstract
Upregulated gene 4 (URG4), a novel gene located on
7 chromosome (7p13), was found to contribute to
hepatocarcinogenesis. However, the role of URG4
in the gastric carcinogenesis still remains unclear.
In the present study, URG4 was found by immuno-
histochemistry to be upregulated in human gastric
cancer tissues compared with matched adjacent non-
neoplastic tissues. The proliferating cell nuclear anti-
gen index is higher in gastric cancer tissues with
high URG4 expression than in those with low URG4
expression. The growth of GES-1 cells, which are im-
mortalized human gastric epithelial mucosa cells with
baseline URG4 expression, was accelerated by URG4
induction. Downregulation of URG4 through URG4
small interfering RNA (siRNA) in SGC7901 and MKN28
cells, which had high endogenous URG4 expression,
suppressed cell proliferation in both of these cells.
URG4-siRNA also inhibited the proliferation of SGC7901
and MKN28 cells in soft agar and tumor formation in
nude mice. Overexpression of URG4 in GES cells up-
regulated cyclin D1, whereas repression of URG4 in
SGC7901 and MKN28 cells downregulated cyclin D1.
The data suggested that URG4 played an important
role in the development of human gastric cancer by re-
gulating the expression of cyclin D1 and might be used
as a potential therapeutic target for gastric cancer.
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Introduction
Cancer is the result of an accumulation of multiple molecular
alterations in the same cell or its descendents [1,2]. Alter-
ations in two groups of genes, proto-oncogenes and tumor-
suppressor genes, play a particularly important role in this
process [3,4]. In the past decade, a very large number of
proto-oncogenes and tumor-suppressor genes have been
found. In spite of the sizable number of genes already
described, new genes with oncogenic potential or tumor-
suppressing activity are still being identified. Recently, upre-
gulated gene 4 (URG4), a novel gene upregulated by HBxAg in
human hepatocellular carcinoma, has been identified (GenBank
accession no. NM_017920) [5].URG4was located on 7 chromo-
some (7p13). Previous data suggested that overexpression of
URG4 in HepG2 cells promoted hepatocellular growth and
survival in tissue culture and nude mice. Hence, URG4 may
be an oncogene operating in hepatocarcinogenesis [5].
Gastric cancer is one of the most common malignancies in
the world, particularly in Eastern Asian countries such as China,
Korea, and Japan [6]. The molecular mechanisms of gastric
carcinogenesis remain unclear. Whether or not URG4 is in-
volved in gastric carcinogenesis is still unknown. To gain insight
into these issues, the expression of URG4 in malignant gastric
tissues and its corresponding adjacent counterparts was
detected, and the effects of the modulation of URG4 gene ex-
pression on the phenotype of gastric cancer cells and on the
immortalized human gastric epithelial mucosa cell line GES-1
were also explored.
Materials and Methods
Tissue Specimens and Cell Lines
Serial sections of paraffin-embedded tissues were collected
from 100 patients with gastric cancer who underwent gastrec-
tomy in our hospital between January 2004 and June 2005.
None of the patients had received preoperative radiation
therapy or chemotherapy. Data on sex, age, tumor size, histo-
logic type of neoplasm, and tumor–node–metastasis (TNM)
stage were obtained from surgical and pathological records,
with the patients’ consent. The human gastric cancer cell lines
Abbreviations: URG4, upregulated gene 4; RT-PCR, reverse transcription– polymerase chain
reaction; siRNA, small interfering RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; PCNA, proliferating cell nuclear antigen
Address all correspondence to: Dr. Jie Liu or Dr. Daiming Fan, Changle West Road, Xi’an,
Shaanxi, China.
E-mail: jieliu@fmmu.edu.cn or fandaim@fmmu.edu.cn
1This work was supported by the Program for New Century Excellent Talents in University and
grants 30371585 and 30570835 from the National Natural Science Foundation of China to
Jie Liu.
2Jiugang Song and Huahong Xie contributed equally to this study.
Received 11 September 2006; Revised 22 October 2006; Accepted 23 October 2006.
Copyright D 2006 Neoplasia Press, Inc. All rights reserved 1522-8002/06/$25.00
DOI 10.1593/neo.06592
Neoplasia . Vol. 8, No. 12, December 2006, pp. 995 –1002 995
www.neoplasia.com
RESEARCH ARTICLE
SGC7901, MKN28, MKN45, AGS, and BGC823, and the im-
mortalized human gastric epithelial mucosa cell line GES-1
were preserved in our institute [7,8]. All cell lines were cultured
in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with
10% heat-inactivated fetal calf serum (FCS) at 37jC with 5%
CO2 in a humidified incubator (Forma Scientific, Marietta, OH).
Immunohistochemical Staining
All sections (4 mm) were cut from original paraffin blocks,
which were deparaffinized in xylene and rehydrated in
graded alcohols. After the inactivation of endogenous per-
oxidase activity with 0.3% hydrogen peroxide in methanol
for 30 minutes, the sections immersed in citrate buffer were
heated in a microwave oven for epitope retrieval. Then the
sections were blocked with 10% normal goat serum (Biologi-
cal Technology Co. Ltd., Wuhan, China) for 40 minutes and
incubated overnight at 4jC with rabbit anti-human URG4
polyclonal antibody (diluted 1:500; kindly provided by Dr. Mark
Feitelson, Department of Pathology, Anatomy, and Cell Biol-
ogy, Thomas Jefferson University, Philadelphia, PA) or mouse
anti-human proliferating cell nuclear antigen (PCNA) mono-
clonal antibody (diluted 1:200; DAKO, Carpinteria, CA). The
primary antibody was detected with the DAKO EnVision+ Kit
(DAKO). Reaction products were visualized with the DAKO
Liquid DAB+ Substrate–Chromagen System (DAKO) and
then counterstained with hematoxylin. Negative control sec-
tions were incubated with preimmune rabbit serum or normal
mouse serum instead of the primary antibody, respectively.
All sections were examined microscopically and scored by
two independent pathologists in a blinded manner. URG4
scoring was based on both intensity and extensity, according
to previous reports [9,10]. The ratio of positive cells per
specimen was evaluated quantitatively and was scored as
follows: 0 = staining of < 1%; 1 = staining of 2% to 25%;
2 = staining of 26% to 50%; 3 = staining of 51% to 75%; and 4 =
staining of > 75%. Intensity was graded as follows: 0 = no
staining; 1 = weak staining; 2 = moderate staining; and 3 =
strong staining. Total score (0–12) was calculated and graded
asnegative (I; score of 0–1),weak (II; score of 2–4),moderate
(III; score of 5–8), and strong (IV; score of 9–12).
For PCNA analysis, the PCNA indexwas examined. It was
calculated as the percentage of PCNA-positive cells per
1000 cells, counted at random in each section. This counting
was performed under a 400 magnification [11].
RNA Extraction and Semiquantitative Reverse
Transcription–Polymerase Chain Reaction (RT-PCR)
Total RNA were isolated from cells with the TRIZOL
Reagent (GIBCO BRL, Grand Island, NY). RT reaction was
performed using the First-Strand cDNA Synthesis Kit (MBI
Fermentas, Vilnius, Lithuania) according to the manufac-
turer’s protocol. Appropriate cycles were chosen to ensure
the termination of PCR amplification before reaching a stable
stage in each reaction. Gene expression was presented as
the yield of PCR products from target sequences relative to
the yield of PCR products from the b-actin gene. PCR primers
and reaction parameters are listed in Table 1. Each experi-
ment was repeated at least thrice.
Plasmid Construction and Transfection
Three pairs of hairpin small interfering RNA (siRNA) oligos
for URG4 were designed according to the siRNA design
guidelines of Ambion, Inc. (Austin, TX) Compare target se-
quences to the human genome database in a BLASTsearch
to eliminate from consideration any target sequence with
more than 16 to 17 base pairs of homology contiguous to
other coding sequences. For oligo-1, sense: 5V-gatccgtgct-
gatgccaggaataccttcaagagaggtattcctggcatcagcattttttggaaa-
3V, antisense: 5V-agcttttccaaaaaatgctgatgccaggaatacctctctt-
gaaggtattcctggcatcagcacg-3V; for oligo-2, sense: 5V-gatccg-
tagaccactcacatgtcctttcaagagaaggacatgtgagtggtctattttttg-
gaaa-3V, antisense: 5V-agcttttccaaaaaatagaccactcacatgtcctt-
ctcttgaaaggacatgtgagtggtctacg-3V; for oligo-3, sense: 5V-
gatccgcttcgaatgcagcagaacgttcaagagacgttctgctgcattc-
gaagttttttggaaa-3V, antisense: 5V-agcttttccaaaaaacttcgaatg-
cagcagaacgtctcttgaacgttctgctgcattcgaagcg-3V. Their target
sequences were homologous to nt 349–369, 1200–1220,
and 1574–1594 of the URG4 cDNA sequence, respectively.
For annealing to form DNA duplexes, 0.01 M each of sense
and antisense oligos was used. The duplexes were diluted
and then ligated with pSilencer3.1-H1 neo vector (Ambion,
Inc.). The products were transformed into DH5a-competent
cells. Ampicillin-resistant colonies were chosen, identified by
restriction digestion, and further confirmed by DNA sequenc-
ing. According to the manufacturer’s instructions, siRNA
plasmids of URG4 were transfected into SGC7901 and
MKN28 cells, and pcDNA3 containing the full-length human
URG4 cDNA (which was also kindly provided by Dr. Mark
Feitelson) was transfected into GES-1 cells using Lipofect-
amine 2000 reagent (Invitrogen, Carlsbad, CA). The cells
transfected with pSilencer3.1-H1 neo vector [which was
provided in the siRNA kit (Ambion, Inc.) and expressed
hairpin siRNA with limited homology to any known sequence
in human genomes] or pcDNA3 vector (Invitrogen) alone
served as negative control, respectively. Cells were selected
in a growth medium containing G418 (Invitrogen). The ex-
pression levels of URG4 in G418-resistant clones were eval-
uated by Western blot analysis.
Cell Proliferation Assays
MTTassay was used to determine the effect of URG4 on
cellular proliferation. Briefly, cells were plated in 96-well
Table 1. Primers and Reaction Parameters for PCR.
Products Sequence Annealing
Temperature (jC)
Number of
Cycles
Size (bp)
URG4 5V-CTTCATCCTGAGTCCCTACCG-3V, 5V-GCCGTTCTGCTGCATTCG-3V 55 32 472
b-Actin 5V-AGCGGGAAATCGTGCGTG-3V, 5V-CAGGGTACATGGTGGTGCC-3V 54 18 309
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plates (2  103 cells/well in a final volume of 200 ml) in
replicates of three. After 1, 2, 3, 4, 5, 6, and 7 days of in-
cubation, 20 ml of MTT (5 mg/ml; Sigma, St. Louis, MO) was
added and incubated for 4 hour. Supernatant was then
removed, and 150 ml of dimethyl sulfoxide was added. Culture
plates were surged for 10 minutes at room temperature to
dissolve MTT crystals. Absorbance values were determined
by an ELISA reader (Bio-Rad Laboratories, Richmond, CA)
at a wavelength of 490 nm. Each experiment was repeated
at least thrice.
Flow Cytometry Assay
For DNA content analysis, cells were harvested and
washed twice with ice-cold phosphate-buffered saline
(PBS). Cell pellets were fixed in 70% ethanol, treated with
RNase A (Boehringer Mannheim, Indianapolis, IN), and
stained with propidium iodide (Sigma-Aldrich, St. Louis,
MO). DNA contents were measured with a flow cytometer
(FACScan; Becton Dickinson, San Jose, CA). The prolifera-
tion index (PI) was calculated as: PI = (S + G2)/(S + G2 + G1).
Western Blot Analysis
Cells were lysed with lysis buffer (50 mM Tris pH 7.2, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, 500 mM NaCl, and 10 mM MgCl2 with
10 mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mM PMSF) and
quantified by the Bradford method. Fifty to sixty micrograms
of cellular proteins was separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (10% gel) and transferred
to nitrocellulose membranes (Immobilin-P; Millipore, Bedford,
MA). Membranes were blocked with 5% nonfat milk at room
temperature for 2 hours and incubated overnight with rabbit
anti-human URG4 polyclonal antibody (diluted 1:800) or
anti–b-actin monoclonal antibody (1:4000; Sigma) at 4jC.
After incubation with horseradish peroxidase–conjugated
anti-rabbit IgG or anti-mouse IgG (Sigma), respectively, the
specific protein band was visualized by enhanced chemilumi-
nescence (Amersham-Pharmacia Biotech, Beijing, China).
Autoradiograms were quantified by densitometry (software:
Bio Image IQ, BioImage, Ann Arbor, MI). The same mem-
brane was reprobed with b-actin–specific antibody to ensure
equal control. Each experiment was repeated at least thrice.
Soft Agar Colony Formation Assays
Anchorage-independent cell growth was determined by
analyzing the formation of colonies in soft agar. Cells (2 
102 cells/well) from each cell line were suspended in 0.3%
agar in RPMI 1640 containing 10% FCS and plated on
solidified agar (0.5%) in 24-well dishes. Cells were incubated
for 3 weeks at 37jC in 5% CO2 before counting colonies
under a code. Each assay was performed in triplicate.
Tumorigenicity Test in Nude Mice
Logarithmically growing cells were trypsinized and resus-
pended in PBS after washing twice with a serum-free me-
dium. About 107 cells in 0.2 ml were injected subcutaneously
into 4-week-old female BALB/c nu/nu mice. After 4 weeks
of observation, the mice were sacrificed and the tumors
were recovered for further analysis. Experimental and con-
trol groups had at least five mice each. Tumor volume
was measured by vernier caliper, and tumor volumes were
calculated according to the formula [12]: Tumor volume
(cm3) = (a/2)(b/2)hp, where a, b, and h are the minor
dimension, major dimension, and height of the tumor, re-
spectively (p = 3.1416).
Statistical Analysis
All data were analyzed using the SPSS software package
(SPSS, Chicago, IL), and P < .05 was considered statistically
significant. The significance of the difference in the frequency
of URG4-positive staining between normal samples and
tumors, and the difference in cell cycle were analyzed by
chi-square test. Mann-Whitney U test for two groups and
Kruskal-Wallis H test followed by Nemenyi test for multi-
groups were used to compare differences among groups on
the immunohistochemistry of URG4 with various clinical
pathological parameters. Student’s t test and one-way anal-
ysis of variance followed by Dunnett’s multiple comparison
tests were adopted for other data.
Results
Immunohistochemical Analysis of URG4 Expression
in Human Gastric Cancer Specimen and Matched
Adjacent Nonneoplastic Tissues
The expression of URG4 in human malignant gastric
tissues and matched adjacent nonneoplastic tissues was
analyzed by immunohistochemistry. The results showed that
URG4 was mainly expressed in the cytoplasm of epithelial
cells and only occasionally in nuclei (Figure 1, A–G). In
gastric cancer tissues, 65% (65 of 100 patients) had positive
staining for URG4 (Figure 1, A–F ), which was significantly
higher than 30% (30 of 100 patients) in adjacent nonneo-
plastic tissues (Figure 1G) (P < .001; Table 2). Further
analysis of the clinicopathological features of 100 gastric
cancer specimens revealed a positive association of URG4
expression with degree of tumor differentiation. In poorly
differentiated tumor cells, the average expression of URG4
was lower, whereas URG4 was detected in most epithelial
cells, with a higher expression in moderately differentiated
and well-differentiated tumor cells (P < .001 and P < .001,
respectively) (Table 3). With respect to TNM stage, the
expression of URG4 was not significantly different between
patients at stages III + IVand patients at stages I + II (P = .133;
Table 3). There was no significant difference in URG4 ex-
pression between tumors with nodal metastasis and those
without (P = .100; Table 3).
Immunohistochemical Analysis of the PCNA Index
in Human Gastric Cancer Tissues
PCNA has been demonstrated to be a useful tool in
evaluating cell proliferation [13]. To determine the gastric
cancer cell PI, the sections were immunohistochemically
stained with PCNA antibody. PCNA protein expression was
observed in the nuclei of cancer cells (Figure 2A). The PCNA
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index of gastric cancer tissues with high URG4 expression is
64.04 ± 11.56, which was higher than 49.84 ± 9.68 in gastric
cancer tissues with low URG4 expression.(P < .01; Table 4)
URG4 mRNA and Protein Expression in Gastric Cancer
Cell Lines
To identify the expression ofURG4 in cell lines, the mRNA
and protein levels of URG4 were determined in five gastric
cancer cell lines and an immortalized gastric epithelial mu-
cosa cell (GES-1). As shown in Figure 3A, a higher expres-
sion of URG4 mRNA was detected in the well-differentiated
gastric cancer cell line MKN28 and in the moderately dif-
ferentiated gastric cancer cell line SGC7901, whereas the
expression of URG4 mRNA was lower in the three poorly
differentiated gastric cell lines BGC823, MKN45, and AGS,
and was lowest in GES-1. The protein expression of URG4
displayed a pattern similar to that in the mRNA level, and a
104-kDa band was detected in all cell lines (Figure 3B).
Overexpression of URG4 Protein Promotes GES-1
Cell Growth
To determine whether URG4 could stimulate the cell
growth and survival of the immortalized human gastric epi-
thelial mucosa cell line GES-1, which had a lower expression
of URG4, pcDNA3-URG4 was transfected into GES-1 cells.
Several G418-resistant clones were obtained after 4 weeks
of selection and then tested for URG4 gene expression at
both mRNA and protein levels. It was found that pcDNA3
URG4 could significantly upregulate the level of URG4
mRNA (Figure 4A) and protein (Figure 4B) compared with
those in controls. Figure 4C showed that GES-1 cells
Figure 1. Immunohistochemical staining of URG4 in normal gastric tissues
and gastric cancer with different stages of differentiation. (A) Anti-URG4
staining of well-differentiated gastric carcinoma tissue. (B) Preimmune rabbit
serum used to stain a consecutive section from the same patient as in (A). (C)
Anti-URG4 staining of moderately differentiated gastric carcinoma tissue. (D)
Preimmune rabbit serum used to stain a consecutive section from the same
patient as in (C). (E) Anti-URG4 staining of poorly differentiated gastric
carcinoma tissue. (F) Preimmune rabbit serum used to stain a consecutive
section from the same patient as in (E). (G) Normal epithelium exhibited
negative URG4 immunostaining. (A–G) Original magnification, 200.
Table 2. Expression of URG4 in Gastric Cancer Tissues and Adjacent
Nonneoplastic Tissues.
Total (n) Positive Negative P
Nonneoplastic tissues 100 30 70 < .001*
Gastric cancer tissues 100 65 35
*P < .05 was considered statistically significant.
Table 3. Clinicopathological Associations of URG4 Expression in Patients
with Gastric Cancer.
Characteristics n URG4 (n) P
I II III IV
Age (years)
< 50 22 7 8 6 1 .455
z 50 78 28 25 22 3
Gender
Male 76 29 26 19 2 .103
Female 24 6 7 9 2
Differentiation
Well-differentiated 17 3 4 7 3 > .100 (well-differentiated
versus moderately
differentiated)
Moderately
differentiated
37 8 12 16 1 < .001* (well-differentiated
versus poorly
differentiated)
Poorly differentiated 46 24 17 5 0 < .001* (moderately
differentiated versus
poorly differentiated)
TNM stage
I + II 53 16 16 18 3 .133
III + IV 47 19 17 10 1
Metastasis
With 34 15 11 7 1 .1
Without 66 20 22 21 3
*P < .05 was considered statistically significant.
Figure 2. Immunohistochemical analysis of the PCNA index in human gastric
cancer tissues. (A) Anti-PCNA staining of gastric carcinoma tissue. (B)
Normal mouse serum used to stain a consecutive section from the same pa-
tient as in (A). (A and B) Original magnification, 200.
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with increased URG4 expression (GES-pcDNA3-URG4)
proliferated at a faster rate than did control cells, and statistical
analysis showed a significant difference in a medium contain-
ing 10% FCS on the third day. The cell cycle of these cells was
then measured with flow cytometry. The results showed that
24.7% of GES-1 cells and 23.5% of GES-pcDNA3 cells were
in S-phase, whereas 49.6% of GES-pcDNA3-URG4 cells
were in S-phase (P < .01; Figure 4D), suggesting that URG4
promotes the entry of cells into S-phase. In addition, this
difference became more striking when the cells were cultured
in a medium supplemented with low concentrations of FCS
(data not shown). Taken together, our data strongly suggest
that upregulation of URG4 promotes cell cycle and, therefore,
enhances the proliferation of GES-1 cells.
Downregulation of URG4 Expression Repressing
the Growth and Tumorigenicity of Gastric Cancer Cells
In Vitro and In Vivo
To determinewhether inhibition ofURG4 expression could
suppress the cell growth of gastric cancer cells, three siRNA
(URG4-siRNA1, URG4-siRNA2, and URG4-siRNA3) that
specifically target URG4 were constructed and transfected
into SGC7901 and MKN28 cells. As seen in Figure 5A, the
expression level of URG4 in MKN28 and SGC7901 cells was
significantly reduced by URG4-siRNA compared to the ex-
pression level of cells transfected with pSilencer3.1-H1 neo
vector alone or parental cells, and URG4-siRNA2 could most
effectively decrease the endogenous level of URG4 protein
compared to URG4-siRNA1 and URG4-siRNA3. Significant
growth inhibition of URG4-siRNA on MKN28 and SGC7901
cells, compared to control cells, was observed from the fourth
day onward (Figure 5B), suggesting that the effects of these
URG4-siRNA on proliferation and viability are likely caused
by the repression of URG4 protein expression. Then, the
effect of URG4-siRNA on the cell cycle of SGC7901 and
MKN28 cells was evaluated by flow cytometry. As seen
in Figure 5C, the percentages for MKN28 and MKN28-
pSilencer cells were 38.2% and 35.8% in S-phase, whereas
20.6% of MKN28-siRNA1, 18.3% of MKN28-siRNA2, and
17.9% of MKN28-siRNA3 cells were in S-phase, respectively
(P < .001). In addition, 43.1% of SGC7901 and 44.9% of
SGC7901-pSilencer cells were in S-phase compared to
23.5% of SGC7901-siRNA1, 19.3% of SGC7901-siRNA2,
and 24.2% of SGC7901-siRNA3 cells (P < .001). Together,
the results showed that URG4-siRNA could repress cell
proliferation by lengthening the cell cycle.
Then, the colony formation assay of parental and trans-
fected cells was measured with plating efficiency in soft agar.
As shown in Figure 5D, MKN28-siRNA1, MKN28-siRNA2,
andMKN28-siRNA3 cells yielded 7.5 ± 1.81, 4.25 ± 1.89, and
6.5 ± 2.51 colonies, whereas MKN28 and MKN28-pSilencer
cells yielded 22 ± 2.58 and 21.5 ± 3.41 colonies after 21 days,
respectively (P < .01). SGC7901-siRNA1, SGC7901-
siRNA2, and SGC7901-siRNA3 cells yielded 12 ± 1.63, 6 ±
1.12, and 7.75 ± 1.26 colonies, whereas SGC7901 and
SGC7901-pSilencer cells yielded 25.75 ± 2.21 and 27.25 ±
2.06 colonies after 21 days, respectively (P < .01). Hence,
the results showed that there was marked reduction in
anchorage-independent growth among cells treated with
URG4-siRNA in comparison with controls. The colonies that
formed in cells treated with URG4-siRNA were considerably
smaller than those in controls (results not shown). Further-
more, the repression potential of URG4-siRNA on the growth
of SGC7901 and MKN28 cells in nude mice was also per-
formed. The result showed that tumor size was dramatically
smaller in SGC7901 and MKN28 cells transfected with
URG4-siRNA2 than in control cells (P < .05; Figure 5E ), sug-
gesting that repression of URG4 was directly involved in
the inhibition of tumor growth in nude mice. In addition,
URG4 protein is much lower in recovered tumors formed in
nude mice injected with SGC7901-siRNA2 than in those with
SGC7901-pSilencer3.1-H1 or parental SGC7901 cells (Fig-
ure 5F ). In conclusion, the data here suggested that URG4
played a promoter role in enhancing the malignant growth
potential of gastric cancer cells in vitro and in vivo.
URG4-Stimulating Cell Proliferation through Cyclin D1
Because URG4 promotes the entry of cells into S-phase,
cyclin D1, a key factor in cell passage through the check
point between G0/G1-phase and S-phase, was further
detected in cell lines with high or low URG4 expression.
The result showed that cyclin D1 was upregulated in
URG4-overexpressed GES-pcDNA3-URG4 cells compared
with GES–pcDNA3 cells and parental cells (Figure 6A).
However, the expression level of cyclin D1 in MKN28 and
Table 4. Associations between PCNA Expression and URG4 Expression in
Gastric Cancer Tissues.
Grade of URG4
Expression
n PCNA Index
(mean ± SD)
P
I + II 32 49.84 ± 9.68 < .01*
III + IV 68 64.04 ± 11.56
*P < .05 was considered statistically significant.
Figure 3. The URG4 expression level of five gastric cancer cell lines and an
immortalized gastric epithelial mucosa cell (GES-1). (A) RT-PCR analysis of
the expression level of URG4 mRNA inGES-1 (lane 1), AGS (lane 2), MKN45
(lane 3), BGC823 (lane 4), MKN28 (lane 5), and SGC7901 (lane 6). -Actin
was used as internal control. (B) Western blot analysis of the expression of
URG4 protein in HepG2 cells (lane 1, positive control) [5], GES-1 (lane 2),
AGS (lane 3), MKN45 (lane 4), BGC823 (lane 5), MKN28 (lane 6), and
SGC7901 (lane 7).
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SGC7901 cells was significantly reduced by URG4-siRNA
compared to cells transfected with pSilencer3.1-H1 neo
vector alone or parental cells, and URG4-siRNA2 could most
effectively decrease the endogenous level of cyclin D1 pro-
tein than could URG4-siRNA1 and URG4-siRNA3 (Figure 6,
B and C). Moreover, cyclin D1 is lower in recovered tumors
formed in nude mice injected with SGC7901-siRNA2 than in
those injected with SGC7901-pSilencer3.1-H1 or parental
SGC7901 cells (Figure 6D).
Discussion
The identification and characterization of genes that are dif-
ferentially expressed in gastric cancer tissues and matched
adjacent nonneoplastic tissues provide important infor-
mation with regard to understanding the mechanisms re-
sponsible for carcinogenesis. In the present study, URG4
expression was found to be upregulated in gastric cancer
tissues compared with matched adjacent nonneoplastic
tissues. This coincides with our in vitro observation that
URG4 is upregulated in gastric cancer cell lines compared
with normal gastric epithelial cell lines, suggesting thatURG4
might play an oncogenic role in the development of gastric
cancer. PCNA, an auxiliary protein of DNA polymerase y, is
a proliferation-associated marker. Its maximal expression
peaks in the late G1-phase and S-phase of the cell cycle
[14]. PCNA has been used as a proliferation marker in dif-
ferent neoplasms. In the present study, the PCNA index of
gastric cancer tissues with high URG4 expression was higher
than those with low URG4 expression, suggesting thatURG4
was related to the proliferative activity of cancer cells and
might promote cell growth in gastric cancer tissues. More-
over, our findings demonstrated that induction ofURG4 could
promote the proliferation of GES-1 cells and could stimulate
cell cycle progression by shortening the emergence of cells
from quiescence (G0) and entry into S-phase. In addition,
reduction of URG4 with URG4-siRNA inhibited the prolif-
eration of SGC7901 and MKN28 cells, and repressed cell
cycle progression. Given that oncogene suppression often
leads to inhibition of the anchorage-independent growth of
tumor cells in soft agar [15], URG4-reducing SGC7901 and
MKN28 cells through siRNA were also tested for anchorage-
independent growth, and the results showed that reduced
URG4 could repress the anchorage-independent growth of
both SGC7901 andMKN28 cells in soft agar (Figure 5D), also
suggesting that URG4 might be an oncogene operating in
gastric carcinogenesis. This was further supported by the
finding that reducing URG4 represses tumor formation and
growth in nude mice (Figure 5, E and F ).
Cyclin D1 is a periodic regulatory protein that is believed
to govern cell cycle transit from G1-phase into S-phase,
and has been found to be abnormally expressed in many
human cancers [16]. Overexpression of cyclin D1 leads to
abnormal cellular proliferation, which underlies the process
Figure 4. Overexpression of URG4 protein promotes GES-1 cell growth. (A) Expression of URG4 mRNA in GES-1 (lane 1), GES-pcDNA3 (lane 2), and GES-
pcDNA3-URG4 (lane 3) by RT-PCR. (B) Expression of URG4 protein in GES-1 (lane 1), GES-pcDNA3 (lane 2), and GES-pcDNA3-URG4 (lane 3) by Western blot
analysis. (C) Growth curves for GES-1, GES-pcDNA3, and GES-pcDNA3-URG4 cells by MTT assay. The value shown is the mean of three determinations.
*Statistical significance. (D) Cell cycle distribution and the PI of GES-1, GES-pcDNA3, and GES-pcDNA3-URG4 cells.
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of tumorigenesis. Thus, cyclin D1 can function as a coopera-
tive oncogene in cell transformation [17]. In the present
study, URG4 could upregulate the expression of cyclin D1,
indicating that cyclin D1 was involved in the contribution of
URG4 to cancer cell growth.
In conclusion, the present study showed that URG4 was
upregulated in human gastric cancer tissues and also in
gastric cancer cell lines, and overexpression of URG4 could
promote cell proliferation, whereas downregulation of URG4
in gastric cancer cells repressed cell proliferation and tumor
formation potential. Moreover, URG4 might promote cell
growth partly through cyclin D1. Our result strongly indicated
that URG4 might be an oncogene involved in the develop-
ment of gastric cancer and also a promising therapeutic target
in cancer treatment.
The mechanism of URG4 biologic activity in normal and
malignant cells is not yet fully understood. Despite ex-
perimental evidence on the oncogenic potential of URG4,
Figure 5. Suppression of gastric cancer cell growth by downregulation of URG4 expression in vitro and in vivo. (A) Western blot analysis of URG4 in parental cells
(P); control vector transfectants (V); and URG4-siRNA1, URG4-siRNA2, and URG4-siRNA3 transfectants (S1, S2, and S3). -Actin was used as loading control.
(B) Growth curves for P, V, S1, S2, and S3 cells by MTT assay. The value shown is the mean of three determinations. *Statistical significance. (C) Cell cycle
distribution and the PI of P, V, S1, S2, and S3 cells by flow cytometry. (D) Colony numbers of P, V, S1, S2, and S3 cells in soft agar. Each soft agar assay was
performed in triplicate, and the results were expressed as the mean number of colonies ± SD. (E) Tumor size of P, V, and S2 cells in BALB/c nu/nu mice. (F) URG4
expression in whole tumor tissue extracts by Western blot analysis. Lane 1, tumor tissue of parental SGC7901. Lane 2, tumor tissue of SGC7901-pSilencer. Lane 3,
tumor tissue of SGC7901-siRNA2.
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preliminary data from our laboratory concerning URG4 sug-
gested that the role ofURG4might be played through the cell
cycle–related protein cyclin D1. Further work should be
pursued in our laboratory to expand these recent findings
and to obtain more information on the function and potential
molecular mechanism(s) of URG4 protein.
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Figure 6. URG4-stimulating cell proliferation through cyclin D1. (A) Expression of cyclin D1 protein in GES-1 (lane 1), GES-pcDNA3 (lane 2), and GES-pcDNA3-
URG4 cells (lane 3) by Western blot analysis. (B) Western blot analysis of cyclin D1 in MKN28 cells (lane 1), control MKN28-pSilencer cells (lane 2), MKN28-
siRNA1 (lane 3), MKN28-siRNA2 (lane 4), and MKN28-siRNA3 (lane 5). -Actin was used as loading control. (C) Western blot analysis of cyclin D1 in SGC7901
cells (lane 1), control SGC7901-pSilencer cells (lane 2), SGC7901-siRNA1 (lane 3), SGC7901-siRNA2 (lane 4), and SGC7901-siRNA3 (lane 5). -Actin was used
as loading control. (D) Cyclin D1 expression in whole tumor tissue extracts by Western blot analysis. Lane 1, tumor tissue of parental SGC7901. Lane 2, tumor
tissue of SGC7901-pSilencer. Lane 3, tumor tissue of SGC7901-siRNA2.
1002 URG4 Contributes to Gastric Carcinogenesis Song et al.
Neoplasia . Vol. 8, No. 12, 2006
